Abatacept biosimilar (Shilpa Biologicals)

阿巴西普生物类似药 (Shilpa Biologicals)

Report date: 2024/08/21 14:09:30

Base Information

Drug NameAbatacept biosimilar (Shilpa Biologicals)
Drug Alias NameSBDM-04
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionCluster of differentiation 80 modulatorsCluster of differentiation 86 modulators
TargetsCluster of differentiation 80Cluster of differentiation 86
Therapy Area/IndicationsPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShilpa Biologicals Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShilpa Biologicals Pvt Ltd
Inactive CompaniesN/A
Active IndicationsPolyarticular Juvenile Idiopathic ArthritisArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A